Green Cross to conduct phase III trial for Peramivir

Green Cross Corporation plans to conduct its local phase III trials with peramivir injection, an important potential therapy for both seasonal influenza and pandemic preparedness as the Korea Food and Drug Administration has recently approved the clinical trial.

Develped by the US based BioCryst Pharmaceuticals Inc., Peramivir is a member of the class of antiviral agents that inhibit influen...